Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin in Obese Subjects With or at Risk for NASH
NCT04880031Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2021
- Primary completion
- Oct 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efimosfermin in Nonalcoholic steatohepatitis (NASH), sponsored by GSK. Started Sep 2021; status: completed.
02
Drugs
efimosfermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04880031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880031.